BioCryst 制药

最新新闻

• Needham Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $16
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• 评级变动
  RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Cuts Target Price to $13
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 评级变动
  BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $15
  \u5e02\u573a\u8d44\u8baf · 2026/2/27
• 评级变动
  Wedbush Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Cuts Target Price to $21
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• 评级变动
  J.P. Morgan Downgrades BioCryst Pharmaceuticals(BCRX.US) to Hold Rating, Cuts Target Price to $12
  \u5e02\u573a\u8d44\u8baf · 2026/7/13
• 评级变动
  J.P. Morgan Initiates a Hold Rating on BioCryst (BCRX)
  TipRanks · 2026/7/13
• 评级变动
  RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Raises Target Price to $14
  \u5e02\u573a\u8d44\u8baf · 2026/7/7
• 评级变动
  Wedbush Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $21
  \u5e02\u573a\u8d44\u8baf · 2026/7/13
• 评级变动
  Wedbush Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Raises Target Price to $22
  \u5e02\u573a\u8d44\u8baf · 2026/3/2
• 评级变动
  A Quick Look at Today's Ratings for BioCryst Pharmaceuticals(BCRX.US), With a Forecast Between $13 to $30
  \u5e02\u573a\u8d44\u8baf · 2026/2/27
• 评级变动
  A Quick Look at Today's Ratings for BioCryst Pharmaceuticals(BCRX.US), With a Forecast Between $16 to $32
  \u5e02\u573a\u8d44\u8baf · 2026/7/1
• 评级变动
  BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/4/16
• Wedbush Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Cuts Target Price to $20
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 评级变动
  TD Cowen Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $30
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 评级变动
  Wedbush Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $22
  \u5e02\u573a\u8d44\u8baf · 2026/3/17
• H.C. Wainwright Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $32
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $13
  \u5e02\u573a\u8d44\u8baf · 2026/3/25
• 评级变动
  BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Announces Target Price $15
  \u5e02\u573a\u8d44\u8baf · 2026/7/15
• J.P. Morgan Maintains BioCryst Pharmaceuticals(BCRX.US) With Hold Rating, Raises Target Price to $13
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• RBC Capital Downgrades BioCryst Pharmaceuticals(BCRX.US) to Hold Rating, Cuts Target Price to $11
  \u5e02\u573a\u8d44\u8baf · 2026/9/10

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。